Background
Methods
Design
Sample and settings
Inclusion criteria
-
Cancer patients who are neurotoxic chemotherapy-naïve and about to receive taxane- and/or platinum-based chemotherapy
-
estimated survival of at least 12 months (as judged by the clinicians)
-
aged 18+ years
-
able to give written informed consent
Sampling and procedures
Outcome measures
Data analysis
Results
Sample characteristics
Characteristic | N | % |
---|---|---|
Sex | ||
Male | 87 | 25.4 |
Female | 256 | 74.6 |
Ethnicity | ||
Chinese | 269 | 78.4 |
Non-Chinese Asian | 31 | 9.0 |
Caucasian | 43 | 12.5 |
Cancer diagnosis | ||
Breast cancer | 174 | 50.7 |
Lung cancer | 48 | 14.0 |
Gynecological cancer | 46 | 13.4 |
Head & Neck cancer | 30 | 8.7 |
Gastrointestinal cancer | 29 | 8.5 |
Urinary tract cancer | 16 | 4.7 |
Cancer stage | ||
I | 52 | 15.2 |
II | 99 | 28.9 |
III | 116 | 33.8 |
IV | 76 | 22.2 |
Treatment intent | ||
Curative | 250 | 72.9 |
Definitive | 30 | 8.7 |
Palliative | 63 | 18.4 |
Type of chemotherapy | ||
Taxane | 155 | 45.2 |
Platinum | 109 | 31.8 |
Combination of taxane plus platinum | 79 | 23.0 |
Chemotherapy protocol | ||
Docetaxel | 122 | 35.6 |
Paclitaxel | 33 | 9.7 |
Cisplatin/Carboplatin | 80 | 23.4 |
Oxaliplatin | 28 | 8.3 |
Carboplatin+Paclitaxel | 49 | 14.4 |
Carboplatin+Docetaxel | 29 | 8.6 |
Prevalence of CIPN
Measures | Baseline | Cycle1 | Cycle2 | Cycle3 | Cycle4 | Cycle5 | Cycle6 | 6mFU | 9mFU | 12mFU | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n/N | % | n/N | % | n/N | % | n/N | % | n/N | % | n/N | % | n/N | % | n/N | % | n/N | % | n/N | % | |
NCI motor1 | ||||||||||||||||||||
Grade 1 | 338/341 | 99.1 | 294/308 | 95.5 | 273/290 | 94.1 | 244/273 | 89.4 | 209/242 | 86.4 | 121/142 | 85.2 | 99/120 | 82.5 | 219/255 | 85.9 | 204/234 | 87.2 | 177/194 | 91.2 |
Grade > =2 | 3/341 | 0.9 | 14/308 | 4.5 | 17/290 | 5.9 | 29/273 | 10.6 | 33/242 | 13.6 | 21/142 | 14.8 |
21/120
|
17.5
| 36/255 | 14.1 | 30/234 | 12.8 | 17/194 | 8.8 |
Grade 2 | 3/341 | 0.9 | 14/308 | 4.5 | 16/290 | 5.5 | 25/273 | 9.2 | 28/242 | 11.6 | 17/142 | 12.0 | 18/120 | 15.0 | 26/255 | 10.2 | 25/234 | 10.7 | 14/194 | 7.2 |
Grade 3 | 1/290 | 0.4 | 4/273 | 1.5 | 5/242 | 2.1 | 4/142 | 2.8 | 3/120 | 2.5 | 10/255 | 3.9 | 5/234 | 2.1 | 3/194 | 1.6 | ||||
NCI sensory1 | ||||||||||||||||||||
Grade 1 | 340/341 | 99.7 | 297/308 | 96.4 | 273/290 | 94.1 | 254/273 | 93.0 | 222/242 | 91.7 | 126/142 | 88.7 | 103/120 | 85.8 | 222/255 | 87.1 | 205/233 | 88.0 | 178/194 | 91.8 |
Grade > =2 | 1/341 | 0.3 | 11/308 | 3.6 | 17/290 | 5.9 | 19/273 | 7.0 | 20/242 | 8.3 | 16/142 | 11.3 |
17/120
|
14.2
| 33/255 | 12.9 | 28/233 | 12.0 | 16/194 | 8.2 |
Grade 2 | 1/341 | 0.3 | 11/308 | 3.6 | 16/290 | 5.5 | 13/273 | 4.8 | 17/242 | 7.0 | 14/142 | 9.9 | 16/120 | 13.3 | 28/255 | 11.0 | 26/233 | 11.2 | 14/194 | 7.2 |
Grade 3 | 1/290 | 0.4 | 6/273 | 2.2 | 3/242 | 1.2 | 2/142 | 1.4 | 1/120 | 0.8 | 5/255 | 2.0 | 2/233 | 0.8 | 2/194 | 1.0 | ||||
WHO CIPN 2 | ||||||||||||||||||||
Grade 0 | 333/341 | 97.7 | 277/308 | 89.9 | 248/290 | 85.5 | 217/273 | 79.5 | 182/242 | 75.2 | 99/142 | 69.7 | 97/120 | 80.8 | 210/255 | 82.4 | 197/234 | 84.2 | 180/194 | 92.8 |
Grade > = 1 | 8/341 | 2.3 | 31/308 | 10.1 | 42/290 | 14.5 | 56/273 | 20.5 | 60/242 | 24.8 |
43/142
|
30.3
| 23/120 | 19.2 | 45/255 | 17.6 | 37/234 | 15.8 | 14/194 | 7.2 |
Grade 1 | 8/341 | 2.3 | 25/308 | 8.1 | 37/290 | 12.8 | 49/273 | 17.9 | 53/242 | 21.9 | 39/142 | 27.5 | 21/120 | 17.5 | 40/255 | 15.7 | 33/234 | 14.1 | 12/194 | 6.2 |
Grade 2 | 5/308 | 1.6 | 3/290 | 1.0 | 6/273 | 2.2 | 7/242 | 2.9 | 3/142 | 2.1 | 2/120 | 1.6 | 5/255 | 2.0 | 4/234 | 1.7 | 2/194 | 1.0 | ||
Grade 3 | 1/308 | 0.3 | 2/290 | 0.7 | 1/273 | 0.4 | 1/142 | 0.7 | ||||||||||||
Cotton wool | ||||||||||||||||||||
Normal (−) | 306/307 | 99.7 | 268/279 | 96.1 | 257/267 | 96.3 | 237/257 | 92.2 | 203/212 | 95.8 | 124/135 | 91.9 | 100/107 | 93.5 | 188/217 | 86.6 | 163/183 | 89.1 | 138/143 | 96.5 |
Abnormal (+) | 1/307 | 0.3 | 11/279 | 3.9 | 10/267 | 3.7 | 20/257 | 7.8 | 9/212 | 4.2 | 11/135 | 8.1 | 7/107 | 6.5 |
29/217
|
13.4
| 20/183 | 10.9 | 5/143 | 3.5 |
A lot of sensation | 4/279 | 1.4 | 8/267 | 3.0 | 2/257 | 0.8 | 3/107 | 2.8 | 3/217 | 1.4 | 6/183 | 3.3 | 1/143 | 0.7 | ||||||
A bit sensation | 1/307 | 0.3 | 1/279 | 0.4 | 1/267 | 0.4 | 2/257 | 0.8 | 2/212 | 0.9 | 1/135 | 0.7 | 21/217 | 9.7 | 12/183 | 6.6 | 4/143 | 2.8 | ||
No sensation | 6/279 | 2.2 | 1/267 | 0.4 | 16/257 | 6.2 | 7/212 | 3.3 | 10/135 | 7.4 | 4/107 | 3.7 | 5/217 | 2.3 | 2/183 | 1.1 | ||||
Monofilament | ||||||||||||||||||||
Normal (−) | 306/307 | 99.7 | 290/302 | 96.0 | 272/290 | 93.8 | 246/273 | 90.1 | 198/220 | 90.0 | 121/142 | 85.2 | 92/106 | 86.8 | 187/232 | 80.6 | 162/196 | 82.7 | 137/147 | 93.2 |
Abnormal (+) | 1/307 | 0.3 | 12/302 | 4.0 | 18/290 | 6.2 | 27/273 | 9.9 | 22/220 | 10.0 | 21/142 | 14.8 | 14/106 | 13.2 |
45/232
|
19.4
| 34/196 | 17.3 | 10/147 | 6.9 |
A lot of sensation | 2/302 | 0.7 | 3/290 | 1.0 | 4/273 | 1.5 | 2/220 | 0.9 | 4/142 | 2.8 | 5/232 | 2.2 | 9/196 | 4.6 | 2/147 | 1.4 | ||||
A bit sensation | 1/307 | 0.3 | 5/302 | 1.7 | 8/290 | 2.8 | 11/273 | 4.0 | 14/220 | 6.4 | 9/142 | 6.3 | 9/106 | 8.5 | 33/232 | 14.2 | 21/196 | 10.7 | 7/147 | 4.8 |
No sensation | 5/302 | 1.7 | 7/290 | 2.4 | 12/273 | 4.4 | 6/220 | 2.7 | 8/142 | 5.6 | 5/106 | 4.7 | 7/232 | 3.0 | 4/196 | 2.1 | 1/147 | 0.7 | ||
ECIPN-20 3 | ||||||||||||||||||||
Numbness in hands/fingers | ||||||||||||||||||||
Grade 1 | 286/342 | 83.6 | 232/306 | 75.8 | 198/287 | 69.0 | 176/271 | 64.9 | 144/240 | 60.0 | 82/138 | 59.4 | 55/118 | 46.6 | 142/255 | 55.7 | 146/234 | 62.4 | 134/195 | 68.8 |
Grade > =2 | 56/342 | 16.4 | 74/306 | 24.2 | 89/287 | 31.0 | 95/271 | 35.1 | 96/240 | 40.0 | 56/138 | 40.6 |
63/118
|
53.4
| 113/255 | 44.3 | 88/234 | 37.6 | 61/195 | 31.2 |
Grade 2 | 50/342 | 14.6 | 55/306 | 18.0 | 62/287 | 21.6 | 72/271 | 26.6 | 66/240 | 27.5 | 36/138 | 26.1 | 36/118 | 30.5 | 73/255 | 28.6 | 67/234 | 28.6 | 49/195 | 25.1 |
Grade 3 | 5/342 | 1.5 | 12/306 | 3.9 | 21/287 | 7.3 | 16/271 | 5.9 | 21/240 | 8.8 | 14/138 | 10.1 | 19/118 | 16.1 | 27/255 | 10.6 | 16/234 | 6.8 | 9/195 | 4.6 |
Grade 4 | 1/342 | 0.3 | 7/306 | 2.3 | 6/287 | 2.1 | 7/271 | 2.6 | 9/240 | 3.8 | 6/138 | 4.3 | 8/118 | 6.8 | 13/255 | 5.1 | 5/234 | 2.1 | 3/195 | 1.5 |
Numbness in feet/toes | ||||||||||||||||||||
Grade 1 | 308/343 | 89.8 | 244/307 | 79.5 | 217/287 | 75.6 | 188/271 | 69.4 | 146/240 | 60.8 | 81/138 | 58.7 | 65/118 | 55.1 | 142/255 | 55.7 | 148/235 | 63.0 | 138/195 | 70.8 |
Grade > =2 | 35/343 | 10.2 | 63/307 | 20.5 | 70/287 | 24.4 | 83/271 | 30.6 | 94/240 | 39.2 | 57/138 |
41.3
|
53/118
|
44.9
| 113/255 | 44.3 | 87/235 | 37.0 | 57/195 | 29.2 |
Grade 2 | 31/343 | 9.0 | 49/307 | 16.0 | 47/287 | 16.4 | 62/271 | 22.9 | 65/240 | 27.1 | 37/138 | 26.8 | 36/118 | 30.5 | 73/255 | 28.6 | 63/235 | 26.8 | 41/195 | 21.0 |
Grade 3 | 2/343 | 0.6 | 10/307 | 3.3 | 16/287 | 5.6 | 12/271 | 4.4 | 22/240 | 9.2 | 13/138 | 9.4 | 12/118 | 10.2 | 29/255 | 11.4 | 16/235 | 6.8 | 11/195 | 5.6 |
Grade 4 | 2/343 | 0.6 | 4/307 | 1.3 | 7/287 | 2.4 | 9/271 | 3.3 | 7/240 | 2.9 | 7/138 | 5.1 | 5/118 | 4.2 | 11/255 | 4.3 | 8/235 | 3.4 | 5/195 | 2.6 |
FACTGOG-Ntx 4 | ||||||||||||||||||||
Numbness/tingling in hands | ||||||||||||||||||||
Grade 0 | 296/343 | 86.3 | 235/307 | 76.5 | 194/287 | 67.6 | 178/271 | 65.7 | 144/240 | 60.0 | 75/138 | 54.3 | 60/119 | 50.4 | 139/255 | 54.5 | 148/235 | 63.0 | 137/195 | 70.3 |
Grade > =1 | 47/343 | 13.7 | 72/307 | 23.5 | 93/287 | 32.4 | 93/271 | 34.3 | 96/240 | 40.0 | 63/138 | 45.7 |
59/119
|
49.6
| 116/255 | 45.5 | 87/235 | 37.0 | 58/195 | 29.7 |
Grade 1 | 39/343 | 11.4 | 42/307 | 13.7 | 57/287 | 19.9 | 61/271 | 22.5 | 61/240 | 25.4 | 36/138 | 26.1 | 33/119 | 27.7 | 65/255 | 25.5 | 61/235 | 26.0 | 37/195 | 19.0 |
Grade 2 | 4/343 | 1.2 | 17/307 | 5.5 | 12/287 | 4.2 | 10/271 | 3.7 | 15/240 | 6.3 | 8/138 | 5.8 | 14/119 | 11.8 | 18/255 | 7.1 | 9/235 | 3.8 | 8/195 | 4.1 |
Grade 3 | 2/343 | 0.6 | 9/307 | 2.9 | 12/287 | 4.2 | 11/271 | 4.1 | 14/240 | 5.8 | 12/138 | 8.7 | 7/119 | 5.9 | 20/255 | 7.8 | 11/235 | 4.7 | 9/195 | 4.6 |
Grade 4 | 2/343 | 0.6 | 4/307 | 1.3 | 12/287 | 4.2 | 11/271 | 4.1 | 6/240 | 2.5 | 7/138 | 5.1 | 5/119 | 4.2 | 13/255 | 5.1 | 6/235 | 2.6 | 4/195 | 2.1 |
Numbness/tingling in feet
| ||||||||||||||||||||
Grade 0 | 317/343 | 92.4 | 247/307 | 80.5 | 215/287 | 74.9 | 183/271 | 67.5 | 146/240 | 60.8 | 79/138 | 57.2 | 70/118 | 59.3 | 137/255 | 53.7 | 150/235 | 63.8 | 143/195 | 73.3 |
Grade > =1 | 26/343 | 7.6 | 60/307 | 19.5 | 72/287 | 25.1 | 88/271 | 32.5 | 94/240 | 39.2 | 59/138 | 42.8 | 48/118 | 40.7 |
118/255
|
46.3
| 85/235 | 36.2 | 52/195 | 26.7 |
Grade 1 | 17/343 | 5.0 | 35/307 | 11.4 | 44/287 | 15.3 | 58/271 | 21.4 | 65/240 | 27.1 | 35/138 | 25.4 | 30/118 | 25.4 | 69/255 | 27.1 | 54/235 | 23.0 | 34/195 | 17.4 |
Grade 2 | 6/343 | 1.7 | 12/307 | 3.9 | 10/287 | 3.5 | 9/271 | 3.3 | 13/240 | 5.4 | 5/138 | 3.6 | 9/118 | 7.6 | 22/255 | 8.6 | 13/235 | 5.5 | 7/195 | 3.6 |
Grade 3 | 2/343 | 0.6 | 7/307 | 2.3 | 10/287 | 3.5 | 11/271 | 4.1 | 10/240 | 4.2 | 13/138 | 9.4 | 6/118 | 5.1 | 17/255 | 6.7 | 9/235 | 3.8 | 9/195 | 4.6 |
Grade 4 | 1/343 | 0.3 | 6/307 | 2.0 | 8/287 | 2.8 | 10/271 | 3.7 | 6/240 | 2.5 | 6/138 | 4.3 | 3/118 | 2.5 | 10/255 | 3.9 | 9/235 | 3.8 | 2/195 | 1.0 |
CIPN measures | Samples | Baseline | Cycle1 | Cycle2 | Cycle3 | Cycle4 | Cycle5 | Cycle6 | 6mFU | 9mFU | 12mFU |
---|---|---|---|---|---|---|---|---|---|---|---|
n/N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | ||
NCI motor 1 (> = grade2) | Docetaxel | 2/122 (1.6) | 3/122 (2.7) | 4/109 (3.7) | 13/105 (12.4) | 21/95 (22.1) | 9/41 (22) | 8/38 (21.1) | 20/96 (20.8) | 19/89 (21.3) | 12/84 (14.3) |
Paclitaxel | 0/33 (0) | 3/33 (9.1) | 2/31 (6.6) | 2/31 (6.4) | 0/28 (0) | 0/13 (0) | 1/13 (7.7) | 5/27 (18.5) | 3/21 (14.3) | 1/15 (6.7) | |
Cisplatin/Carboplatin | 1/80 (1.2) | 2/65 (3.1) | 5/57 (8.8) | 6/46 (13) | 4/32 (12.5) | 1/9 (11.1) | 0/6 (0) | 3/43 (7) | 3/39 (7.7) | 2/32 (6.2) | |
Oxaliplatin | 0/28 (0) | 2/26 (7.7) | 2/25 (8) | 0/22 (0) | 0/22 (0) | 0/16 (0) | 1/11 (9.1) | 1/21 (4.8) | 0/17 (0) | 0/12 (0) | |
Carboplatin+paclitaxel | 0/49 (0) | 3/44 (6.8) | 2/42 (4.8) | 6/42 (14.3) | 6/38 (15.8) | 6/30 (20) | 5/24 (20.8) | 14/24 (58.3) | 5/40 (12.5) | 2/24 (8.3) | |
Carboplatin+docetaxel | 0/29 (0) | 1/28 (3.6) | 2/26 (7.7) | 2/27 (7.4) | 2/27 (7.4) | 5/26 (17.9) | 6/28 (21.4) | 1/28 (3.6) | 0/28 (0) | 0/27 (0) | |
NCI sensory1 (> = grade2) | Docetaxel | 0/122 (0) | 1/122 (0.9) | 4/109 (3.7) | 7/105 (6.7) | 10/95 (10.5) | 5/41 (12.2) | 4/38 (10.5) | 17/96 (17.7) | 17/89 (19.1) | 9/84 (10.7) |
Paclitaxel | 0/33 (0) | 3/33 (9.1) | 3/31 (9.7) | 2/31 (6.14) | 0/28 (0) | 0/18 (0) | 3/13 (23.1) | 7/27 (25.9) | 4/21 (19) | 2/15 (13.4) | |
Cisplatin/Carboplatin | 1/80 (1.2) | 0/65 (0) | 4/57 (7.0) | 4/46 (8.7) | 2/32 (6.3) | 1/9 (11.1) | 0/6 (0) | 2/43 (4.7) | 3/39 (7.7) | 2/32 (6.2) | |
Oxaliplatin | 0/28 (0) | 2/26 (7.7) | 2/25 (8) | 0/22 (0) | 0/22 (0) | 0/16 (0) | 1/11 (9.1) | 1/21 (4.8) | 1/17 (5.9) | 0/12 (0) | |
Carboplatin+paclitaxel | 0/49 (0) | 5/44 (11.4) | 3/42 (7.1) | 5/42 (11.9) | 7/38 (18.4) | 7/30 (23.3) | 7/27 (29.2) | 6/40 (15) | 4/40 (10) | 3/24 (12.5) | |
Carboplatin+docetaxel | 0/29 (0) | 0/28 (0) | 1/26 (3.8) | 1/27 (3.7) | 1/27 (3.7) | 3/28 (10.7) | 2/28 (7.1) | 0/28 (0) | 0/28 (0) | 0/27 (0) | |
WHO-CIPN 2 (> = grade 1) | Docetaxel | 1/122 (0.8) | 3/122 (2.7) | 5/109 (4.6) | 8/105 (7.6) | 11/95 (11.6) | 7/41 (17.1) | 5/38 (13.2) | 16/96 (16.7) | 15/89 (16.9) | 9/84 (10.7) |
Paclitaxel | 2/33 (6.1) | 9/33 (27.3) | 10/31 (32.3) | 16/31 (51.6) | 16/28 (57.1) | 0/18 (0) | 7/13 (53.8) | 14/27 (51.9) | 8/21 (38.1) | 2/15 (13.3) | |
Cisplatin/Carboplatin | 1/80 (1.2) | 2/65 (3) | 6/57 (10.5) | 3/46 (6.5) | 1/32 (3.1) | 0/9 (0) | 0/6 (0) | 2/43 (4.7) | 1/39 (2.6) | 1/32 (3.1) | |
Oxaliplatin | 2/28 (7.1) | 6/26 (23.1) | 9/25 (36) | 14/22 (63.6) | 12/22 (54.5) | 9/16 (56.3) | 3/11 (27.3) | 4/21 (19) | 6/17 (35.3) | 1/12 (8.3) | |
Carboplatin+paclitaxel | 2/49 (4) | 11/44 (25) | 12/42 (28.6) | 15/42 (35.7) | 19/38 (50) | 13/30 (43.3) | 5/19 (20.8) | 7/40 (17.5) | 7/40 (17.5) | 1/24 (4.2) | |
Carboplatin+docetaxel | 0/29 (0) | 0/28 (0) | 0/26 (0) | 0/27 (0) | 1/27 (3.7) | 2/28 (7.1) | 3/28 (10.7) | 2/28 (7.1) | 0/28 (0) | 0/27 (0) | |
Cotton wool(+)3 | Docetaxel | 1/113 (0.9) | 2/104 (1.9) | 2/104 (1.9) | 2/100 (1.2) | 1/84 (1.2) | 1/38 (2.6) | 2/31 (6.5) | 6/82 (7.3) | 4/64 (6.3) | 2/57 (3.5) |
Paclitaxel | 0/31 (0) | 3/33 (9.1) | 1/29 (3.4) | 5/29 (17.2) | 0/28 (0) | 2/18 (11.1) | 1/13 (7.7) | 7/25 (28) | 7/20 (35) | 2/14 (14.3) | |
Cisplatin/Carboplatin | 0/65 (0) | 1/55 (1.8) | 0/48 (0.0) | 0/43 (0) | 0/16 (0) | 0/8 (0) | 0/3 (0) | 1/29 (3.4) | 2/26 (7.7) | 0/19 0) | |
Oxaliplatin | 0/27 (0) | 3/25 (12.0) | 3/25 (12) | 5/22 (22.7) | 3/16 (18.8) | 2/12 (16.7) | 8/20 (40) | 3/16 (18.8) | 1/12 (8.3) | 1/12 (8.3) | |
Carboplatin+paclitaxel | 0/49 (0) | 6/36 (8.3) | 4/35 (11.4) | 8/36 (22.2) | 6/29 (17.1) | 4/27 (14.8) | 1/20 (5) | 6/33 (18.2) | 4/31 (12.9) | 0/16 (0) | |
Carboplatin+docetaxel | 0/29 (0) | 0/28 (0) | 0/26 (0) | 0/27 (0) | 0/27 (0) | 1/28 (3.6) | 1/28 (3.6) | 1/28 (3.6) | 0/26 (0) | 0/25 (0) | |
Monofilame-nt(+)3 | Docetaxel | 1/116 (0.9) | 2/109 (1.8) | 4/109 (3.7) | 5/105 (4.8) | 7/88 (8) | 5/41 (12.2) | 5/31 (16.1) | 16/85 (18.8) | 12/68 (17.6) | 4/57 (7.0) |
Paclitaxel | 1/33 (3.0) | 9/33 (27.3) | 3/31 (9.7) | 5/31 (16.1) | 0/31 (0) | 1/18 (5.6) | 1/13 (7.7) | 7/27 (25.9) | 8/21 (38.1) | 3/15 (20.0) | |
Cisplatin/Carboplatin | 0/77 (0) | 1/63 (1.6) | 2/57 (3.5) | 2/46 (4.3) | 1/17 (5.9) | 1/9 (0) | 0/3 (0) | 3/33 (9.1) | 3/29 (10.3) | 0/21 (0) | |
Oxaliplatin | 0/28 (0) | 2/26 (7.7) | 3/25 (12) | 4/22 (18.2) | 2/22 (9.1) | 3/16 (18.8) | 1/11 (9.1) | 7/21 (33.3) | 4/17 (23.5) | 1/12 (8.3) | |
Carboplatin+paclitaxel | 0/49 (0) | 4/43 (9.3) | 6/42 (14.3) | 11/42 (26.2) | 11/38 (28.9) | 9/30 (30) | 4/20 (20) | 10/38 (26.3) | 7/35 (20) | 2/17 (11.8) | |
Carboplatin+docetaxel | 0/29 (0) | 0/28 (0) | 0/26 (0) | 0/27 (0) | 1/27 (3.7) | 2/28 (7.1) | 3/28 (10.7) | 2/28 (7.1) | 0/26 (0) | 0/25 (0) | |
FACTGOG-Ntx Numbness/tingling in hands 5 (>grade = 1) | Docetaxel | 21/122 (17.2) | 20/113 (17.7) | 26/109 (23.9) | 29/105 (27.6) | 36/96 (37.5) | 19/41 (46.3) | 17/38 (44.7) | 41/96 (42.7) | 36/90 (40) | 22/84 (26.2) |
Paclitaxel | 7/33 (21.2) | 11/32 (34.4) | 13/31 (41.9) | 15/31 (41.9) | 13/28 (48.4) | 8/18 (44.4) | 9/13 (69.2) | 17/27 (63) | 11/21 (52.4) | 10/15 (66.7) | |
Cisplatin/Carboplatin | 11/81 (13.6) | 7/66 (10.6) | 9/57 (15.8) | 9/47 (19.1) | 6/32 (18.7) | 2/9 (22.2) | 3/6 (50) | 11/43 (25.6) | 7/39 (17.9) | 3/32 (9.4) | |
Oxaliplatin | 2/28 (7.1) | 10/24 (41.7) | 15/26 (65.2) | 15/20 (75) | 15/20 (75) | 8/14 (57.1) | 5/9 (55.6) | 15/21 (71.4) | 11/17 (64.7) | 10/12 (83.3) | |
Carboplatin+paclitaxel | 5/50 (10) | 23/44 (52.4) | 25/41 (61.0) | 22/41 (53.7) | 22/37 (59.5) | 18/28 (64.3) | 13/25 (52) | 22/40 (55) | 16/40 (40) | 8/25 (32) | |
Carboplatin+docetaxel | 1/29 (3.4) | 1/28 (3.6) | 5/26 (19.2) | 3/27 (11.1) | 4/27 (14.8) | 8/28 (28.6) | 12/28 (42.9) | 10/28 (35.7) | 6/28 (21.4) | 5/27 (18.5) | |
FACTGOG-Ntx Numbness/tingling in feet 5 (>grade = 1) | Docetaxel | 6/122 (4.9) | 10/113 (8.8) | 12/109 (11) | 22/105 (21) | 29/96 (30.2) | 12/41 (29.3) | 9/38 (23.7) | 37/96 (38.5) | 31/90 (34.4) | 21/84 (25.0) |
Paclitaxel | 5/32 (15.6) | 11/31 (35.5) | 13/31 (41.9) | 15/31 (8.4) | 14/28 (50) | 8/18 (44.4) | 7/13 (53.8) | 16/27 (59.3) | 10/21 (47.6) | 7/15 (46.7) | |
Cisplatin/Carboplatin | 5/81 (6.2) | 7/66 (10.6) | 5/57 (8.8) | 7/47 (14.9) | 7/32 (21.9) | 3/9 (33.3) | 3/6 (50) | 14/43 (32.6) | 8/39 (20.5) | 2/32 (6.2) | |
Oxaliplatin | 2/28 (7.2) | 9/27 (37.5) | 16/23 (69.6) | 13/20 (65) | 15/20 (75) | 8/14 (57.1) | 3/9 (33.3) | 15/21 (71.4) | 5/21 (23.8) | 9/12 (75.0) | |
Carboplatin+paclitaxel | 5/50 (10) | 20/44 (45.5) | 22/41 (53.7) | 26/41 (63.4) | 23/37 (62.2) | 20/28 (71.4) | 13/25 (52) | 26/40 (75) | 19/40 (47.5) | 8/25 (32) | |
Carboplatin+docetaxel | 1/29 (3.4) | 2/28 (7.1) | 4/26 (15.4) | 5/27 (18.5) | 6/27 (22.2) | 8/28 (28.6) | 13/28 (46.4) | 10/28 (35.7) | 6/28 (21.4) | 5/27 (18.5) | |
ECIPN-20 (item 3) Numbness inhands/fingers 4 (> = grade 2) | Docetaxel | 26/122 (21.3) | 22/113 (19.5) | 24/109 (22) | 31/105 (29.5) | 36/96 (37.5) | 17/41 (41.5) | 18/38 (47.4) | 41/96 (42.7) | 36/89 (40.4) | 25/84 (29.8) |
Paclitaxel | 6/33 (18.2) | 11/31 (35.5) | 13/31 (41.9) | 14/31 (45.2) | 13/28 (46.4) | 6/18 (33.3) | 10/13 (76.9) | 10/27 (59.3) | 10/21 (47.6) | 8/15 (53.3) | |
Cisplatin/Carboplatin | 12/81 (14.8) | 5/66 (7.6) | 9/57 (15.8) | 9/47 (19.1) | 6/32 (18.7) | 3/9 (33.3) | 3/6 (50) | 11/43 25.6) | 8/39 (20.5) | 4/32 (22.5) | |
Oxaliplatin | 6/28 (21.4) | 14/24 (58.8) | 17/23 (73.9) | 14/20 (70.0) | 14/20 (70.0) | 8/14 (57.1) | 6/9 (66.6) | 14/21 (66.7) | 10/17 (38.1) | 8/12 (66.7) | |
Carboplatin+paclitaxel | 5/50 (10) | 20/44 (45.5) | 22/41 (53.7) | 23/41 (56.1) | 23/37 (62.2) | 15/28 (53.6) | 13/24 (54.2) | 22/40 (55) | 16/40 (40) | 10/25 (40) | |
Carboplatin+docetaxel | 2/29 (6.9) | 2/28 (7.1) | 4/26 (15.4) | 4/27 (14.8) | 4/27 (14.8) | 7/28 (25) | 11/28 (39.3) | 9/28 (32.1) | 7/28 (25) | 6/27 (22.2) | |
ECIPN-20 (item 4) Numbness in feet/toes 4 (> = grade 2) | Docetaxel | 8/122 (6.6) | 12/113 (10.6) | 15/109 (13.8) | 23/105 (21.9) | 30/96 (31.2) | 10/41 (24.4) | 11/38 (29.0) | 37/96 (38.5) | 31/90 (34.4) | 24/84 (28.6) |
Paclitaxel | 7/33 (21.2) | 12/32 (37.5) | 11/31 (35.5) | 11/31 (35.5) | 14/28 (50.0) | 9/18 (50.0) | 8/13 (61.5) | 15/27 (55.6) | 6/15 (40) | ||
Cisplatin/Carboplatin | 8/81 (9.9) | 4/66 (6.1) | 6/57 (10.5) | 7/47 (14.9) | 5/32 (15.6) | 3/9 (33.3) | 3/6 (50) | 11/43 (25.6) | 9/39 (23.1) | 3/32 (9.4) | |
Oxaliplatin | 3/28 (10.7) | 10/24 (41.7) | 14/9 (60.1) | 14/20 (70.0) | 14/20 (70) | 7/14 (50.0) | 4/9 (44.4) | 13/21 (61.9) | 10/17 (58.8) | 8/12 (66.7) | |
Carboplatin+paclitaxel | 7/50 (14) | 23/44 (52.3) | 21/41951.2) | 24/41 (58.5) | 25/37 (67.6) | 20/28 (71.4) | 15/24 (62.5) | 27/40 (67.5) | 21/40 (52.5) | 11/25 (440 | |
Carboplatin+docetaxel | 2/29 (6.9) | 2/28 (7.1) | 3/26 (11.5) | 4/27 (14.8) | 6/27 (22.2) | 8/28 (28.6) | 13/28 (46.4) | 10/28 (35.7) | 6/28 (21.4) | 5/27 (18.5) |
Cumulative chemotherapy dose and CIPN
Abnormal | |||||
---|---|---|---|---|---|
Drug | NCI CTCAE motor | NCI CTCAE sensory | WHO CIPN | Cotton wool | Monofilament |
Oxaliplatin-based regimens (n = 27, observations = 196) | 1.15 (0.90, 1.47) | 1.25 (0.94, 1.67) | 1.13 (0.95, 1.34) | 1.32* (1.06, 1.64) | 1.42* (1.06, 1.89) |
Carboplatin AUC (in 1 unit) (n = 88, observations = 657) | 1.03 (0.98, 1.08) | 1.06* (1.01, 1.10) | 0.98 (0.93, 1.03) | 0.93* (0.88, 0.99) | 0.96 (0.92, 1.01) |
Cisplatin-based regimens (n = 70, observations = 362) | 0.89 (0.55, 1.46) | 0.90 (0.55, 1.49) | 1.43 (0.94, 2.19) | 1.28 (0.57, 2.91) | 1.37 (0.86, 2.17) |
Paclitaxel-based regimens (n = 83, observations = 621) | 1.02 (0.83, 1.25) | 1.01 (0.85, 1.20) | 1.01 (0.92, 1.11) | 0.91 (0.80, 1.04) | 0.94 (0.84, 1.06) |
Docetaxel-based regimens (n = 151, observations = 1167) | 0.96 (0.69, 1.32) | 1.03 (0.69, 1.52) | 1.36 (0.91, 2.04) | 2.12 (0.93, 4.81) | 1.47 (0.96, 2.25) |